<DOC>
	<DOCNO>NCT01014351</DOCNO>
	<brief_summary>Based data demonstrate synergy paclitaxel mammalian target rapamycin ( mTOR ) inhibition , investigator propose addition everolimus paclitaxel carboplatin lead improvement efficacy measure progression-free survival response rate .</brief_summary>
	<brief_title>Study Everolimus With Paclitaxel Carboplatin Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically confirm metastatic melanoma . 2 . Stage III IV disease amenable resection . 3 . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . If patient previous radiation target lesion ( ) , must evidence progression since radiation . 4 . ECOG Performance Status 0 1 . 5 . Life expectancy ≥12 week . 6 . No prior cytotoxic chemotherapy target therapy . Immunotherapy allow ( i.e. , interleukin2 interferon ) . 7 . Adequate hematological function : absolute neutrophil count ( ANC ) ≥1500/µL platelet ≥100,000/µL hemoglobin &gt; 9 g/dL 8 . Adequate renal function : serum creatinine ≤2.0 mg/dL calculate ( measure ) GFR ≥50 mL/min . 9 . Adequate hepatic function : serum bilirubin ≤1.5 x institutional upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 × ULN , ≤5 × ULN patient document liver metastasis . 10 . Normal PT , INR . Patients coumadin anticoagulation eligible stable dose , INR therapeutic range . 11 . Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . 12 . Age ≥18 year . 13 . Ability swallow whole pill . 14 . Patient must accessible treatment followup . 15 . Patients must able understand investigational nature study give write informed consent prior study entry . 1 . Previous treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) , paclitaxel , carboplatin . 2 . Treatment investigational agent ≤4 week protocol treatment . 3 . Patients currently receive anticancer therapy receive anticancer therapy ≤3 week start study drug ( include radiation therapy , immunotherapy ) . 4 . Patients , major surgery significant traumatic injury ≤4 week start study drug patient recover side effect major surgery ( define require general anesthesia ) . 5 . Patients receive chronic , systemic treatment corticosteroid ( dose &gt; 10 mg daily methylprednisolone equivalent ) immunosuppressive agent . Topical inhale steroid allow . 6 . Immunization attenuate live vaccine ≤1 week study anytime study treatment period . 7 . Patients active brain metastasis ineligible . Patients treat brain metastasis eligible ( 1 ) radiation therapy complete ≥4 week prior study entry ; ( 2 ) surgery complete ≥4 week prior study entry ; ( 3 ) followup scan show disease progression ; ( 4 ) patient require steroid . 8 . Any severe and/or uncontrolled medical condition condition could affect participation study : severely impaired lung function define DLCO ≤50 % normal predict value and/or O2 saturation ≤88 % rest room air . symptomatic congestive heart failure New York Heart Association Class III IV . unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant disease . uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN . active ( acute chronic ) uncontrolled severe infection . liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . 9 . Active , bleed diathesis . 10 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 11 . A known history human immunodeficiency virus ( HIV ) seropositivity . 12 . Known hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients . 13 . Use St. John 's Wort prohibit . Drugs substance ( e.g. , grapefruit , star fruit , seville orange , juice product ) , know inhibitor inducer isoenzyme CYP3A4 avoid . Coadministration substrates , inducer , inhibitor P glycoprotein also avoid . 14 . Female patient pregnant breastfeed adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . Hormonal contraceptives acceptable sole method contraception . ( Women childbearing potential [ WOCBP ] must negative urine serum pregnancy test within 7 day prior administration everolimus . ) WOCBP continue use effective contraception 8 week end everolimus treatment . 15 . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . 16 . History noncompliance medical regimen . Patients unwilling , unable , comply protocol . 17 . History disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition may render patient high risk treatment complication use agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
</DOC>